The UK medical cannabis sector operates under a complex regulatory framework, heavily influenced by the MHRA, Home Office, and, for novel ingestible CBD products, the FSA. This intricate interplay necessitates meticulous compliance from all operators, from cultivators to pharmacies.

Recent discussions within the industry have brought to light a concerning aspect of patient access: the significant concentration of prescribing activity. Reports suggest that a small number of clinicians are responsible for a disproportionately large volume of medical cannabis prescriptions. While specific figures can be elusive in a largely private market, the qualitative concern is clear: a system over-reliant on a limited pool of prescribers inherently carries heightened risk.

Why Prescriber Concentration Matters for UK Operators

This isn't merely a point of academic interest. For sponsors, Responsible Persons (RPs), wholesalers, and boards, this concentration introduces several critical vulnerabilities and compliance challenges:

Business Continuity and Supply Chain Risk

Imagine the impact on patient access and your supply chain if a few key prescribers were to face regulatory scrutiny, unexpected leave, or withdrawal from practice. For operators importing and distributing medical cannabis, this translates directly to demand volatility and potential stockholding issues. Boards must consider whether their reliance on existing channels is sustainable and whether diversification strategies are adequately in place.

Regulatory Scrutiny and Professional Standards

The MHRA and General Medical Council (GMC) maintain stringent standards for prescribing practices, particularly for controlled drugs. A high volume of prescriptions from a small number of prescribers can attract closer examination. Operators have an indirect stake in the professional standards of the prescribers they serve. While direct control is limited, understanding and monitoring trends in prescribing patterns can inform risk assessments and identify potential areas of concern that might eventually impact your business partners.

Patient Safeguarding and Clinical Governance

A diversified base of prescribers typically indicates a healthier, more robust system where prescribing decisions are distributed and peer-reviewed more broadly. Concentration can raise questions about clinical governance, patient choice, and the potential for a limited range of therapeutic approaches. This isn't just about regulatory adherence; it's about the ethical imperative to ensure diverse, high-quality patient care.

Wholesaler Due Diligence and RP Responsibilities

Wholesale Distribution Authorisation (WDA(H)) holders and their RPs have clear responsibilities for due diligence on their customers, including pharmacies and dispensing clinics. While not directly overseeing prescribing doctors, the RP must ensure that medicinal products are supplied only to those legally entitled to receive them and that robust systems are in place to prevent diversion or misuse. An unusual concentration of demand from specific clinics, potentially linked to a few prescribers, should trigger enhanced scrutiny and risk assessment as part of routine RP oversight.

Medicexum's View: Proactive Risk Management is Key

At Medicexum, we believe this issue underscores the urgent need for robust internal governance and proactive risk management within UK medicinal cannabis businesses. Boards and senior leadership must move beyond passive observation and actively engage with data to understand their operational ecosystem. This means:

  • Mapping the Prescribing Landscape: While sensitive, operators should endeavour to understand the general patterns of prescribing within the market they serve. This intelligence is vital for strategic planning and mitigating supply risks.
  • Enhancing Wholesaler Due Diligence: RPs must review and, if necessary, strengthen their due diligence processes for customer onboarding and ongoing monitoring. This includes scrutinising orders that appear unusually large or inconsistent with typical demand profiles for a given clinic.
  • Advocating for System Diversification: While individual operators cannot dictate prescribing practices, the industry as a whole shares an interest in a diverse and robust prescriber base. Industry bodies and leading operators should advocate for initiatives that encourage more doctors to become confident and competent prescribers of medical cannabis.
  • Robust Quality Management Systems: Ensure your Quality Management System (QMS) adequately addresses supply chain risks stemming from potential changes in prescribing patterns. Scenario planning for major disruptions is crucial.

The concentration of medical cannabis prescribing in the UK is a symptom of a still-nascent market, but one that presents tangible risks that operators cannot afford to ignore. Proactive engagement with these challenges will not only bolster your business's resilience but also contribute to the sustainable and responsible growth of the wider UK medicinal cannabis sector.

Source: Do 10 Doctors Really Prescribe Half of England's Medical Cannabis?